Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Hepatology. 2020 Apr 27;72(2):441–453. doi: 10.1002/hep.31046

Fig. 2. Safety and Pharmacokinetics.

Fig. 2.

(A) Safety and tolerability of F-652 as determined by absence of significant adverse events (SAE). There were no SAE related to the study drug leading to discontinuation. (B) Pharmacokinetics showing half-life of F-652. The half-life of F-652 following the first dose was 61-85 h.